CURE Pharmaceutical [OTC: CURR] Expands Highly Valuable Medication Patent Portfolio; Marketing Expansion to Mexico, Plus New Product Applications in the Multi-Billion Dollar Erectile Dysfunction Market

Ø  InnovativeMedication Development & Enhancement Company.

Ø  Patentsfor Extraction, Concentration & Processing of Specialized MedicinalCompounds.

Ø   New Marketing to Mexico in Collaboration withFactoria Bogar Subsidiary.

Ø  NewOral Thin Film Products for High Value Erectile Dysfunction Market.

On June 3rdCURE Pharmaceutical (OTC:CURR), an innovative medication development andenhancement company, announced a collaboration with PMI, a subsidiary of FactoriaBogar in Guadalajara, Mexico. PMI will have access to the CURR bio-productplatform, CUREform™ for its medicationformulation, and become its distribution partner in Mexico for CURR wellnessproducts, such as its vitamin D supplement, sleep and specialized botanicalextract products.

The CURRweekly vitamin D supplements provide 50,000 IU of vitamin D3 to reduce the riskof infections. CURR sleep strips contain a soothing blend of melatonin,naturally occurring amino acids and beneficial vitamins that promote fast-acting,balanced sleep patterns for a deep, restful slumber and a rejuvenatedawakening. 

The PMIcollaboration will include several development initiatives with its proprietaryprebiotic product from Agave in combination with special botanical extracts thatleverage the CURR CUREform™ novel delivery platform for treatment ofmultiple GI indications. There are patient studies planned for Mexico toimprove medication efficacy with CURR extracts and prebiotics.

Ø  NewPatents Issued on Key Therapeutics for Infectious Diseases

On April 21stCURR announced the issuance of two U.S. Patents: No. 10,639,339 and10,624,940. The patents represent an expansion of the existing CURR“product by process” patents for obtaining multiple unique concentrates usingsuper critical fluid extraction (SCFE). These include concentrates which haveshown promising therapeutic activity in animal studies in areas such asinflammatory bowel disease, cancer and infectious diseases.

Additionally,CURR is granting equipment manufacturers, processing companies and drugdevelopers licenses to its portfolio of issued and pending process andcomposition patents for isolating specific botanical compounds using anadvanced SCFE technology utilizing carbon dioxide as the solvent. While thepatents cover the incorporation of extracts into multiple dosage forms, CURRhas retained all rights to applying these methods in oral thin films.

The two new CURRpatents cover the extraction and purification of specialized plant material, aswell as subsequent processing of extracts for medication formulations. Thisextraction and fractioning of bioactive molecules allows for the integration ofmolecules into dosage forms.

Ø  NewApplications in the Multi-Billion Dollar Erectile Dysfunction Market

This newsfollows up on a CURR announcement of March 17th whichdetailed the allowance of Chinese Patent No. ZL201480039313.6 regarding theloading of high amounts of active drug on an oral thin film using itsproprietary drug delivery systems. This new patent includes the company’s leadproduct, CUREfilm Blue™, a soluble thinfilm for oral administration of sildenafil citrate to treat erectiledysfunction (ED) in China.

The ED drugmarket is expected to reach USD $6.5 billion ata 6% compound annual growth rate by 2025, according to QYResearch. The report points out that the AsiaPacific market will be one of the fastest growing markets for EDmedicine. Sildenafil is leading the ED drug market worldwide with morethan half of all global sales.

The CURRED patent covers methods of preparing edible thin films that can deliver highdoses of active ingredients that are encapsulated using lipids to form micellesor liposomes. This enables CURR to differentiate its oral thin filmproduct from sildenafil oral soluble films.

For moreInformation visit the CURR company website at: https://www.curepharmaceutical.com/

###